Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 51 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Pharma Officinalis from Ternat, company number BE0842146872, closed financial year 2025 with a result of € 113,149 after tax. For that financial year Pharma Officinalis recorded a gross margin of € 183,843 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 157,311 to € 113,149. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 1.3 million
▲ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 113,149
▼ 28% vs 2024
Profit after tax over the fiscal year.
€ 8,907
▲ 91% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 842 paid out
1 % of the profit went to the shareholders, the rest stayed in the company.
Debts at end 2025
€ 395,367
▼ 23% vs 2024
€ 121,020 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 3,969
▲ 64% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 18,301
▼ 47% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 194,062 | € 194,437 | € 248,859 | € 183,843 | ▼ 26% |
| Profit after taxes | € 164,752 | € 108,530 | € 157,311 | € 113,149 | ▼ 28% |
| Equity | € 922,659 | € 1,030,347 | € 1,186,790 | € 1,299,097 | ▲ 9% |
| Total debts | € 881,712 | € 762,417 | € 642,308 | € 534,389 | ▼ 17% |
| Cash | € 7,132 | € 372 | € 4,653 | € 8,907 | ▲ 91% |
| Retained profit | € 916,459 | € 1,024,147 | € 1,180,590 | € 1,292,897 | ▲ 10% |
| Dividend | € 810 | € 842 | € 868 | € 842 | ▼ 3% |
| Bank debt | € 717,443 | € 637,757 | € 512,587 | € 395,367 | ▼ 23% |
| Balance sheet total | € 1,804,371 | € 1,792,764 | € 1,829,098 | € 1,833,485 |
Key figures of Pharma Officinalis, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Pharma Officinalis?
What happened at Pharma Officinalis in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 113,149 (▼ 28% vs 2024). Source: NBB ↗
- New establishment in Ternat. KBO
- Start of the company according to the CBE. KBO
In short
From € 164,752 profit in 2022 to € 113,149 profit in 2025.
Paid € 214,611 in corporate taxes since 2022.
Best year ever: 2022, with € 164,752 profit.
Paid out € 3,362 in dividends to the owners in total.
Management
Behind Pharma Officinalis is Sven Lenaerts. It owns 100% of Apotheek Opwijk Lenaerts and 25% of Pharma4Future itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Weverstraat 12
1741 Ternat
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0842.146.872
- VAT number
- BE 0842.146.872
- Registered office
- Weverstraat 12, 1741 Ternat
- Names & denominations
- Pharma Officinalis
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 December 2011
- Peppol
- Active · Active since 31 Aug 2023
- Activities · NACE
Detailhandel in farmaceutische producten